AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15217654 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane‐induced hypotension
Number of subjects: 24
Study 15217654 — intervention group
Group type: COMPARATOR
Intervention: Normotension (Control group)
Number of subjects: 24
Study 11432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised concentration-controlled trial (RCCT)
Number of subjects: 0
Study 11432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised effect-controlled trial (RECT)
Number of subjects: 0
Study 11432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised biomarker-controlled trial (RBCT)
Number of subjects: 0
Study 11432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised dose-controlled trial (RDCT)
Number of subjects: 0
Study 9686663 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate stage HIE (n = 7)
Number of subjects: 39
Study 9686663 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe stage HIE (n = 8)
Number of subjects: 39
Study 9686663 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy term newborns, n = 35)
Number of subjects: 39
Study 8625167 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 124
Study 8625167 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 and PEG-IL-2 combination
Number of subjects: 124
Study 8625167 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IL-2
Number of subjects: 124
Study 2166654 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms SMS (somatostatin analogue)
Number of subjects: 7
Study 2166654 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (250 micrograms or 63 micrograms)
Number of subjects: 7
Study 2166654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7358476 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride (1%)
Number of subjects: 24
Study 7358476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31452038 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week mindfulness protocol
Number of subjects: 141
Study 31452038 — intervention group
Group type: COMPARATOR
Intervention: 6-week course containing organizational aspects of the medical school
Number of subjects: 141
Study 30920645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326
Study 30920645 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) chemotherapy
Number of subjects: 326
Study 28743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a single dose in the range of 15-24 Gy
Number of subjects: 9
Study 28743240 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) in five fractions of 4 Gy to a total dose of 20 Gy
Number of subjects: 9
Study 28743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 9
Study 28743240 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 9
Study 26036936 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI/FLAIR mismatch
Number of subjects: 197
Study 26036936 — intervention group
Group type: COMPARATOR
Intervention: PWI/DWI mismatch
Number of subjects: 197
Study 23432360 — intervention group
Group type: EXPERIMENTAL
Intervention: diet
Number of subjects: 439
Study 23432360 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 439
Study 23432360 — intervention group
Group type: EXPERIMENTAL
Intervention: diet + exercise
Number of subjects: 439
Study 23432360 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 439
Study 22368796 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival group
Number of subjects: 16
Study 22368796 — intervention group
Group type: COMPARATOR
Intervention: Gingival crest group
Number of subjects: 16
Study 22368796 — intervention group
Group type: COMPARATOR
Intervention: Comparison between subgingival and gingival crest groups
Number of subjects: 16
Study 19412613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pain therapy (Group 2)
Number of subjects: 492
Study 19412613 — intervention group
Group type: COMPARATOR
Intervention: Individual and surgery-dependent pain therapy (Group 1)
Number of subjects: 492
Study 18593536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 68
Study 18593536 — intervention group
Group type: COMPARATOR
Intervention: Simple observation
Number of subjects: 68
Study 15161791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1038
Study 15161791 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 1038
Study 15161791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocytokines
Number of subjects: 1038
Study 15161791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin, IL‐6, and PAI‐1
Number of subjects: 1038
Study 11164762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study 9550533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense nonpharmacological intervention including a low-fat, high-fiber diet and regular daily physical exercise
Number of subjects: 108
Study 8064367 — intervention group
Group type: EXPERIMENTAL
Intervention: 210 mumol of vitamin A
Number of subjects: 345
Study 8064367 — intervention group
Group type: COMPARATOR
Intervention: 105 mumol of vitamin A
Number of subjects: 345
Study 3291938 — intervention group
Group type: EXPERIMENTAL
Intervention: Epostane (3-beta hydroxy steroid dehydrogenase inhibitor)
Number of subjects: 0
Study 3291938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 30744430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar fluid (BALF) and plasma biomarkers measured at baseline, day 4 ± 1, and day 8 ± 1.
Number of subjects: 90
Study 30744430 — intervention group
Group type: COMPARATOR
Intervention: Historical controls from previous studies (1999 RCT and 2007 biomarker study).
Number of subjects: 90
Study 28912050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) for 28 days
Number of subjects: 90
Study 28912050 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 90
Study 24345055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (n=9) - treated by the same protocol twice a day
Number of subjects: 18
Study 24345055 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (n=9) - received physical therapy according to daily custom protocol
Number of subjects: 18
Study 23149867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy with applied relaxation (n = 33)
Number of subjects: 60
Study 23149867 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (n = 27)
Number of subjects: 60
Study 22049293 — intervention group
Group type: COMPARATOR
Intervention: Regular bread (control group: n = 39)
Number of subjects: 116
Study 22049293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with salt content gradually lowered by 52% (reduced group: n = 38)
Number of subjects: 116
Study 22049293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with salt content gradually lowered by 67% (reduced group: n = 38)
Number of subjects: 116
Study 22049293 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor compensated bread with salt content gradually lowered by 67% (compensated group: n = 39)
Number of subjects: 116
Study 22049293 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt reduction in bread (with and without flavor compensation)
Number of subjects: 116
Study 19001484 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of the CONSORT checklist for pragmatic trials
Number of subjects: 0
Study 19001484 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16358329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic nerve block applied to the intact hand
Number of subjects: 0
Study 16358329 — intervention group
Group type: COMPARATOR
Intervention: Intact foot anesthesia
Number of subjects: 0
Study 16358329 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 0
Study 12637470 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine plus cytarabine (ara‐C)
Number of subjects: 87
Study 12637470 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine plus topotecan
Number of subjects: 87
Study 12637470 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine plus idarubicin
Number of subjects: 87
Study 12637470 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine-based combinations
Number of subjects: 87
Study 10758468 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA applied around the base of the affected hallux for at least 1 hour before ring block
Number of subjects: 55
Study 10758468 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 55
Study 8925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Gear ratio of 8.87 FR/PCR
Number of subjects: 10
Study 8925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Gear ratios of 8.00, 8.87, and 10.06 FR/PCR
Number of subjects: 10
Study 8925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Gear ratio maximizing PPO (8.87 FR/PCR)
Number of subjects: 10
Study 8925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing gear ratios
Number of subjects: 10
Study 1372652 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 8
Study 1372652 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 3901375 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0
Study 3901375 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 0
Study 3901375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and bupivacaine
Number of subjects: 0
Study 3901375 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline solution
Number of subjects: 0
Study 3901375 — intervention group
Group type: COMPARATOR
Intervention: No epidural catheter
Number of subjects: 0
Study 31368268 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to unilateral Neixiyan (EX-LE5) and Waixiyan (EX-LE5) for 20 min at 20 Hz
Number of subjects: 40
Study 31368268 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue relaxing needling (relaxing-needling)
Number of subjects: 40
Study 31368268 — intervention group
Group type: COMPARATOR
Intervention: Comparison of relaxing-needling vs. EA
Number of subjects: 40
Study 30488889 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 15000
Study 30488889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15000
Study 26969417 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-436 (1,000 mg)
Number of subjects: 20
Study 26969417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 20
Study 26969417 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ABT-436
Number of subjects: 20
Study 26969417 — intervention group
Group type: COMPARATOR
Intervention: Placebo for alcohol
Number of subjects: 20
Study 24527853 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (single application of PDT using a 638-nm laser and toluidine blue)
Number of subjects: 22
Study 24527853 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 22
Study 22192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 μg
Number of subjects: 23
Study 22192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone-salmeterol combination, 500/50 μg
Number of subjects: 23
Study 22192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 μg
Number of subjects: 23
Study 22192967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21129343 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen Echo
Number of subjects: 205
Study 21129343 — intervention group
Group type: COMPARATOR
Intervention: NovoPen Junior
Number of subjects: 205
Study 21129343 — intervention group
Group type: COMPARATOR
Intervention: HumaPen Luxura HD
Number of subjects: 205
Study 18411915 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine 80 mg
Number of subjects: 345
Study 18411915 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 345
Study 14693963 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (O)
Number of subjects: 39
Study 14693963 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention combined with placebo (Int+P)
Number of subjects: 39
Study 14693963 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention combined with orlistat (Int+O)
Number of subjects: 39
Study 11910714 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by nurses providing health and lifestyle advice
Number of subjects: 683
Study 9653597 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential new agent for diabetic neuropathy (no efficacy demonstrated)
Number of subjects: 1035
Study 9653597 — intervention group
Group type: COMPARATOR
Intervention: Standardized foot care education
Number of subjects: 1035
Study 9653597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT)
Number of subjects: 1035
Study 9653597 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan DPN scores for muscle strength and reflexes
Number of subjects: 1035
Study 7858504 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification chemotherapy
Number of subjects: 192
Study 7858504 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance therapy
Number of subjects: 192
Study 2918589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous prostaglandin E1
Number of subjects: 48
Study 2918589 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine plus papaverine
Number of subjects: 48
Study 31904292 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone added to bupivacaine and epinephrine nerve blocks
Number of subjects: 49
Study 31904292 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and epinephrine nerve blocks without dexamethasone
Number of subjects: 49
Study 28687482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus nab-paclitaxel with nintedanib (150 mg twice daily)
Number of subjects: 170
Study 28687482 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus nab-paclitaxel alone
Number of subjects: 170
Study 26385396 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208 200 mg
Number of subjects: 323
Study 26385396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 24290532 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (300-600mg/day) in RCT
Number of subjects: 827
Study 24290532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600mg/day) in clinical practice study
Number of subjects: 827
Study 23712500 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcoming Anorexia Online with clinician guidance (OAO-G)
Number of subjects: 37
Study 23712500 — intervention group
Group type: COMPARATOR
Intervention: Overcoming Anorexia Online without clinician guidance (OAO-NoG)
Number of subjects: 37
Study 21623749 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded review
Number of subjects: 40
Study 21623749 — intervention group
Group type: COMPARATOR
Intervention: Unblinded review
Number of subjects: 40
Study 19087482 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pharmacological treatment
Number of subjects: 42
Study 19087482 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 42
Study 16554515 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-only stimuli
Number of subjects: 0
Study 16554515 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-surround stimuli
Number of subjects: 0
Study 16554515 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-only and center-surround stimuli
Number of subjects: 0
Study 12655621 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 43
Study 12655621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11185671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) dosage form of clomipramine
Number of subjects: 18
Study 11185671 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) dosage form of clomipramine
Number of subjects: 18
Study 9264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene measures, water sanitation, and oral rehydration therapy
Number of subjects: 0
Study 1532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 2357
Study 1532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2357
Study 1532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 2357
Study 1532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 2357
Study 1532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antihypertensive therapy
Number of subjects: 2357
Study 3898450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (IP 5-FU)
Number of subjects: 66
Study 3898450 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil (IV 5-FU)
Number of subjects: 66
Study 30521970 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 222
Study 30521970 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VP)
Number of subjects: 222
Study 29370844 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS-AQ Winthrop®)
Number of subjects: 636
Study 29370844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®)
Number of subjects: 636
Study 29370844 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LM, Coartem®)
Number of subjects: 636
Study 27555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral silymarin 420 mg daily in three divided doses for 6 weeks
Number of subjects: 27
Study 27555604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24507426 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 11
Study 24507426 — intervention group
Group type: COMPARATOR
Intervention: MDCT
Number of subjects: 11
Study 21703792 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 70
Study 21703792 — intervention group
Group type: COMPARATOR
Intervention: Colour Doppler Ultrasonography (CDUS)
Number of subjects: 70
Study 21703792 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA after balloon angioplasty
Number of subjects: 70
Study 21703792 — intervention group
Group type: COMPARATOR
Intervention: CDUS after balloon angioplasty
Number of subjects: 70
Study 21703792 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA after stent implantation
Number of subjects: 70
Study 21703792 — intervention group
Group type: COMPARATOR
Intervention: CDUS after stent implantation
Number of subjects: 70
Study 21703792 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA
Number of subjects: 70
Study 21703792 — intervention group
Group type: COMPARATOR
Intervention: CDUS
Number of subjects: 70
Study 20194956 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isokinetic hamstring exercises starting at postoperative 3 weeks (group I)
Number of subjects: 48
Study 20194956 — intervention group
Group type: COMPARATOR
Intervention: Daily isokinetic hamstring exercises starting at postoperative 9 weeks (group II)
Number of subjects: 48
Study 18343263 — intervention group
Group type: EXPERIMENTAL
Intervention: ER‐DP+ASA 200/25 mg BID
Number of subjects: 60
Study 18343263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d
Number of subjects: 60
Study 18343263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d plus ASA 81 mg/d
Number of subjects: 60
Study 17146312 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-training
Number of subjects: 180
Study 17146312 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-training
Number of subjects: 180
Study 17146312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 12701778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of Depo‐Medrol (40 mg)
Number of subjects: 40
Study 12701778 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of sterile saline placebo (control)
Number of subjects: 40
Study 11088092 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheters
Number of subjects: 27878
Study 11088092 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheters
Number of subjects: 27878
Study 9372647 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 20 mg/d in a prospectively tapered regimen (P)
Number of subjects: 37
Study 9372647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with prednisone 20 mg/d and cyclosporin A 5 to 7 mg/kg/d (P-CsA)
Number of subjects: 37
Study 1552108 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 1552108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3005774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen 20 mg/m2 Days 2-6 and premarin 0.625 mg Q 12-H X 3 on Day 7
Number of subjects: 110
Study 3005774 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without additional hormones
Number of subjects: 110
Study 3005774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin in patients with inflammatory breast cancer
Number of subjects: 110
Study 3005774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin
Number of subjects: 110
Study 30388714 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone
Number of subjects: 116
Study 30388714 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free normal saline (placebo)
Number of subjects: 116